DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines
Vaccination remains the most effective and essential prophylactic tool against infectious diseases. Enormous efforts have been made to develop effective vaccines against malaria but successes remain so far limited. Novel adjuvants may offer a significant advantage in the development of malaria vacci...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
MDPI
2018
|
| _version_ | 1797105977866059776 |
|---|---|
| author | Cabral-Miranda, G Salman, AM Mohsen, MO Storni, FL Roesti, ES Skinner, MA Heath, MD Kramer, MF Khan, SM Janse, CJ Hill, AVS Bachmann, MF |
| author_facet | Cabral-Miranda, G Salman, AM Mohsen, MO Storni, FL Roesti, ES Skinner, MA Heath, MD Kramer, MF Khan, SM Janse, CJ Hill, AVS Bachmann, MF |
| author_sort | Cabral-Miranda, G |
| collection | OXFORD |
| description | Vaccination remains the most effective and essential prophylactic tool against infectious diseases. Enormous efforts have been made to develop effective vaccines against malaria but successes remain so far limited. Novel adjuvants may offer a significant advantage in the development of malaria vaccines, in particular if combined with inherently immunogenic platforms, such as virus-like particles (VLP). Dioleoyl phosphatidylserine (DOPS), which is expressed on the outer surface of apoptotic cells, represents a novel adjuvant candidate that may confer significant advantage over existing adjuvants, such as alum. In the current study we assessed the potential of DOPS to serve as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP using Plasmodium falciparum thrombospondin-related adhesive protein (TRAP) as a target antigen. TRAP was chemically coupled to VLPs derived from the cucumber mosaic virus fused to a universal T cell epitope of tetanus toxin (CuMVtt). Mice were immunized with TRAP alone or formulated in alum or DOPS and compared to TRAP coupled to CuMVtt formulated in PBS or DOPS. Induced immune responses, in particular T cell responses, were assessed as the major protective effector cell population induced by TRAP. The protective capacity of the various formulations was assessed using a transgenic Plasmodium berghei expressing PfTRAP. All vaccine formulations using adjuvants and/or VLP increased humoral and T cell immunogenicity for PfTRAP compared to the antigen alone. Display on VLPs, in particular if formulated with DOPS, induced the strongest and most protective immune response. Thus, the combination of VLP with DOPS may harness properties of both immunogenic components and optimally enhance induction of protective immune responses. |
| first_indexed | 2024-03-07T06:55:07Z |
| format | Journal article |
| id | oxford-uuid:fde3abbb-98e2-402c-817d-9270694cc061 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:55:07Z |
| publishDate | 2018 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oxford-uuid:fde3abbb-98e2-402c-817d-9270694cc0612022-03-27T13:32:04ZDOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccinesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fde3abbb-98e2-402c-817d-9270694cc061EnglishSymplectic Elements at OxfordMDPI2018Cabral-Miranda, GSalman, AMMohsen, MOStorni, FLRoesti, ESSkinner, MAHeath, MDKramer, MFKhan, SMJanse, CJHill, AVSBachmann, MFVaccination remains the most effective and essential prophylactic tool against infectious diseases. Enormous efforts have been made to develop effective vaccines against malaria but successes remain so far limited. Novel adjuvants may offer a significant advantage in the development of malaria vaccines, in particular if combined with inherently immunogenic platforms, such as virus-like particles (VLP). Dioleoyl phosphatidylserine (DOPS), which is expressed on the outer surface of apoptotic cells, represents a novel adjuvant candidate that may confer significant advantage over existing adjuvants, such as alum. In the current study we assessed the potential of DOPS to serve as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP using Plasmodium falciparum thrombospondin-related adhesive protein (TRAP) as a target antigen. TRAP was chemically coupled to VLPs derived from the cucumber mosaic virus fused to a universal T cell epitope of tetanus toxin (CuMVtt). Mice were immunized with TRAP alone or formulated in alum or DOPS and compared to TRAP coupled to CuMVtt formulated in PBS or DOPS. Induced immune responses, in particular T cell responses, were assessed as the major protective effector cell population induced by TRAP. The protective capacity of the various formulations was assessed using a transgenic Plasmodium berghei expressing PfTRAP. All vaccine formulations using adjuvants and/or VLP increased humoral and T cell immunogenicity for PfTRAP compared to the antigen alone. Display on VLPs, in particular if formulated with DOPS, induced the strongest and most protective immune response. Thus, the combination of VLP with DOPS may harness properties of both immunogenic components and optimally enhance induction of protective immune responses. |
| spellingShingle | Cabral-Miranda, G Salman, AM Mohsen, MO Storni, FL Roesti, ES Skinner, MA Heath, MD Kramer, MF Khan, SM Janse, CJ Hill, AVS Bachmann, MF DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines |
| title | DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines |
| title_full | DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines |
| title_fullStr | DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines |
| title_full_unstemmed | DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines |
| title_short | DOPS adjuvant confers enhanced protection against malaria for VLP-TRAP based vaccines |
| title_sort | dops adjuvant confers enhanced protection against malaria for vlp trap based vaccines |
| work_keys_str_mv | AT cabralmirandag dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT salmanam dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT mohsenmo dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT stornifl dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT roesties dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT skinnerma dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT heathmd dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT kramermf dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT khansm dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT jansecj dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT hillavs dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines AT bachmannmf dopsadjuvantconfersenhancedprotectionagainstmalariaforvlptrapbasedvaccines |